Author

Marzieh K. Golmakani

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

BACKGROUND Atirmociclib is a potential first-in-class, highly selective cyclin-dependent kinase (CDK) 4 inhibitor, demonstrating significantly greater selectivity over CDK6. In a phase 1/2a study, atirmociclib plus endocrine therapy was well tolerated and showed encouraging antitumor activity in patients with HR+/HER2-...

A. Giordano, B. Xu, T. Yoshinami et al. · Annals of Oncology · 0 citations

Open access Sep 2026

A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers

In this phase I, first-in-human phase I study, PF-07062119 monotherapy demonstrated a generally tolerable safety profile within the context of this early-phase study with evidence of clinical activity in patients with advanced/metastatic GI cancers.

M. Fakih, Toshihiko Doi, A. Tolcher et al. · Cancer Research Communicatio... · 0 citations